<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448978</url>
  </required_header>
  <id_info>
    <org_study_id>241-59-88</org_study_id>
    <nct_id>NCT03448978</nct_id>
  </id_info>
  <brief_title>Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma</brief_title>
  <official_title>Combined Phase I-Phase II Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cartesian Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cartesian Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I/II study will test the safety and anti-myeloma activity of ascending doses of
      Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in
      eligible patients with active multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 26, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]. Descriptive statistics by incidence rate, body system classification, severity, and causality [per protocol definitions]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response</measure>
    <time_frame>1, 3, 6, 9 and 12 months</time_frame>
    <description>IMWG treatment response criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Descartes-08 plus fludarabine/cyclophosphamide pretreat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Descartes-08</intervention_name>
    <description>autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor</description>
    <arm_group_label>Descartes-08 plus fludarabine/cyclophosphamide pretreat</arm_group_label>
    <other_name>CAR-T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>intravenous fludarabine</description>
    <arm_group_label>Descartes-08 plus fludarabine/cyclophosphamide pretreat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>intravenous cyclophosphamide</description>
    <arm_group_label>Descartes-08 plus fludarabine/cyclophosphamide pretreat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (condensed):

          -  Multiple myeloma that is double-refractory to a proteasome inhibitor (PI) and an
             immunomodulatory drug (IMiD) after at least 2 prior lines of therapy OR have failed at
             least 3 prior lines of therapy

          -  Measurable disease activity as indicated by serum or urine M-protein, serum free light
             chain, biopsy-proven plasmacytoma, &gt;5% bone marrow plasma cells.

          -  Adequate vital organ function as indicated by ANC (&gt;1000/uL), platelet count
             (&gt;50,000/uL), hemoglobin (&gt;8 g/dL), serum ALT and AST (each &lt;3.0 x upper limit of
             normal), total bilirubin (&lt;2 mg/dL), creatinine clearance (&gt;30 mL/min), and cardiac
             ejection fraction (&gt;45%)

        Exclusion Criteria (condensed):

        NOTE: Prior anti-BCMA or CAR-T therapy is NOT exclusionary

          -  Active plasma cell leukemia

          -  Pregnant or lactating

          -  Active, uncontrolled infection

          -  Active and severe auto-immune disease

          -  Active arrhythmia, or obstructive or restrictive pulmonary disease

          -  Central nervous system disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Metin Kurtoglu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cartesian Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cartesian Coordinator for Clinical Trials</last_name>
    <phone>302-648-6497</phone>
    <email>trials@cartesiantx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Dormal</last_name>
      <phone>203-833-2701</phone>
    </contact>
    <contact_backup>
      <last_name>Iris Isufi, MD</last_name>
      <phone>203-200-4363</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgetown University Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Billings Cancer Clinic</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Bosket</last_name>
      <email>KBosket@billingsclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Palka Anand</last_name>
      <phone>551-996-3040</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Reep</last_name>
      <phone>405-271-8001</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virgina Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Descartes-08</keyword>
  <keyword>CAR T Cell</keyword>
  <keyword>CART</keyword>
  <keyword>CAR-T</keyword>
  <keyword>CAR T-Cell</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>BCMA</keyword>
  <keyword>B-cell maturation antigen</keyword>
  <keyword>B cell maturation antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

